Drug to drug interaction with NSAIDS.
Sensitize body tissue to insulin: stimulates insulin receptor sites.
Inhibit production of glucose by the liver.
Usually given once a day.
Do not increased insulin secretion.
Increase and prolong the action of the hormone that increases insulin release and decreases glucagon levels.
Stimulate beta cells of the pancreas.
Prevents kidneys from reabsorbing glucose.
Possible side-effect of impaired platelet function.
Stimulate pancreas to secrete insulin.
Enhances glucose-dependent insulin secretion.
Dipeptidyl Pepidase-4 Inhibitors (sitagliptin/Januvia, vildagliptin /Galvus)
Januvia
Avandia
Sodium-glucose co-transporter 2 inhibitors (empagliflozin/Jardiance
Biguanides (metformin (Glucophage) Metformin with glyburide (Glucovance)
Thiazolidinediones (pioglitazone (actos, rosiglitazone/Avandia)
Alpha-glucosidase inhibitors (acarbose/Precose, miglitol (Glyset)
Non-sulfonylurea insulin secretagogues (repaglinide/Prandin, nateglinide/Starlix)
Glucagon-like peptide-1 agonist (liraglutide/Victoza,, dulaglutide/Trulicity)
glipizide
Second generation sulfonylureas (glipizide (Glucotrol) Glyburide (DiaBeta) Glimepiride (Amaryl)